The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | The current treatment landscape for CLL
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of the Barts Cancer Institute, London, UK, presents an overview of the updated results of the Phase III MURANO study (NCT02005471), specifically the impact of peripheral blood measurable residual disease (MRD) on long-term clinical outcomes following venetoclax plus rituximab (VenR) vs. bendamustine plus rituximab (BR) in chronic lymphocytic leukemia (CLL) patients. Prof. Gribben also discusses several studies evaluating the use of CAR T-cells in CLL, with notable efficacy and safety results for CD19-directed JCAR014 alone or in combination with ibrutinib for treating relapsed/refractory CLL.
